Journal
PHYTOMEDICINE
Volume 59, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.phymed.2019.152910
Keywords
Longan fruit extract; Osteoclast differentiation; Bone mineral density; RANKL; NF-kappa B
Categories
Funding
- High Value-added Food Technology Development Program [114030-3]
- Ministry of Agriculture, Food and Rural Affairs
Ask authors/readers for more resources
Background: The receptor activator of nuclear factor-kappa B ligand (RANKL)-induced nuclear factor-kappa B (NF-kappa B) signaling pathway plays essential roles in osteoclast differentiation and may serve as an attractive target for the development of therapeutics for osteoporosis. Purpose: This study aimed to identify plant extracts that attenuated RANKL-induced NF-kappa B signaling pathway and examine their anti-osteoporotic effects in animal model systems. Methods: Osteoclast differentiation was determined by western blot analysis, RT-PCR, and tartrate-resistant acid phosphatase (TRAP) assay. The effect of Longan (Dimocarpus longan Lour.) fruit extract (LFE) on bone mineral density was evaluated by calcein staining in zebrafish and micro-CT analysis in ovariectomized (OVX) rat. Results: LFE nullified RANKL-induced down-regulation of inhibitor of NF-kappa B, which keeps NF-kappa B sequestered in the cytosol, thereby inhibiting translocation of NF-kappa B to the nucleus, in RAW264.7 cells. In addition, LFE decreased the nuclear levels of c-Fos and nuclear factor of activated T-cells c1, which play crucial roles in RANKL-induced osteoclast differentiation, in RAW264.7 cells. LFE repressed RANKL-activated cathepsin K and TRAP expression in RAW264.7 cells, resulting in a reduction of the number of TRAP-positive multinucleated cells, without cytotoxicity. Furthermore, LFE increased bone mineralization in zebrafish and prevented bone loss in OVX rat. Conclusion: Collectively, our findings suggest that LFE exerts its anti-osteoporotic activity through inhibition of osteoclast differentiation and may have potential as a herbal therapeutic or preventive agent for the treatment of osteoporosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available